GCGR and metabolic dysfunction-associated steatotic liver disease: Others have shown that the beneficial effects of the glucagon receptor/GLP1R co-agonist cotadutide on blood glucose and bodyweight are predominantly mediated by the GLP1R, while the effects on NAFLD require glucagon receptor activation (27).